Drug Trial Radar · NCT00023244
Steroid Withdrawal in Pediatric Kidney Transplant Recipients
Last checked: Nov 19, 2026Latest source record: Oct 21, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
274
Actual
Start
Jan 2001
Primary completion
Jun 2005
Study completion Jun 2005
Sponsor
- Sponsor type
- NIH
- Collaborators
- Cooperative Clinical Trials in Pediatric Transplantation
- First posted
- Aug 31, 2001
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 day, up to 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to examine the effects of withdrawing steroids on graft rejection and kidney functions in kidney transplant recipients between the ages of 0 and 20 years (prior to their 21st birthday). Graft survival has improved in recent years in children with kidney transplants. One bad side effect of steroid maintenance therapy has been growth retardation. Doctors believe steroids might be safely withdrawn in patients that are receiving other maintenance therapies. If steroids are removed, children might catch up in their growth and also might have fewer side effects of other kinds. This study evaluates whether steroid therapy can be withdrawn in a way that does not increase graft rejection.
Conditions
- End-Stage Renal Disease
Interventions
BasiliximabDrug
Administered as a bolus intravenous injection. The first dose is given pre-operatively, the second dose is given on post-transplant day four. Dosage is determined by individual weight.
CyclosporineDrug
Participants receiving cyclosporine microemulsion formula (in lieu of tacrolimus) will have the dose adjusted to maintain a whole blood trough Abbott TDx assay monoclonal level of 175-400 ng/mL (or an equivalent high pressure liquid chromatography (HPLC) level) for the first 2 weeks after transplant. The dose will subsequently be tapered to maintain a trough level of 175-300 ng/mL from week 3 to month 3, and 50-250 ng/mL from month 3 through the end of the study at month 36 (year 3).
TacrolimusDrug
Participants receiving tacrolimus (in lieu of Cyclosporine) will have the dose adjusted to maintain a whole blood trough level between 10 and 15 ng/mL for the first 4weeks after transplant. Trough levels will be maintained between 5 and 10 ng/mL thereafter throughout the duration of the study.
SirolimusDrug
Participants take daily (orally, either as tablets or as liquid) starting on postoperative day 1 at a dose of 6 mg/m2 and will be adjusted to maintain a trough level of 10-20 ng/mL throughout the study.
MethylprednisoloneDrug
Administered at 10 mg/kg intravenously perioperatively and on postoperative day 1.
PrednisoneDrug
Administered orally beginning on Post-Op Day 2 and maintained for all participants until day 180. Randomization will determine whether patients will maintain this treatment following day 180.
BactrimDrug
All subjects will receive TMP SMX (Bactrim), pneumocystis jiroveci (carinii) prophylaxis, beginning on postoperative day 1 and continuing for 6 months following transplant. Dosage: 10 mg/kg taken orally three times weekly (maximum dose 160 mg).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Growth, measured as change in standardized height from 6 month to 2.5 years post-transplantationTime frame: At 6 months and 2.5 years post-transplant
Locations
19 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama
UCSD Medical Center
San Diego, California
Denver Children's Hospital
Aurora, Colorado
University of Florida Health Science Center
Jacksonville, Florida
Emory Children's Center
Atlanta, Georgia
Tulane University Medical Center
New Orleans, Louisiana
University of Maryland Medical Center
Baltimore, Maryland
Children's Hospital of Boston
Boston, Massachusetts
University of New Mexico Health Science Center
Albuquerque, New Mexico
The Children's Hospital of Buffalo
Buffalo, New York
Westchester Medical Center
Valhalla, New York
Rainbow Babies and Childrens Hospital
Cleveland, Ohio
University Hospitals of Cleveland
Cleveland, Ohio
Penn State College of Medicine
Hershey, Pennsylvania
LeBonheur Children's Medical Center
Memphis, Tennessee
Christopher Goldsbury Center
San Antonio, Texas
Children's Hospital and Regional Medical Center
Seattle, Washington
University of Wisconsin
Madison, Wisconsin
Hospital Infantil de Mexico
Mexico City, Mexico City, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.